Najeh Hcini1, Fatma Maamri2, Olivier Picone3, Jean-Francois Carod4, Véronique Lambert2, Meredith Mathieu2, Gabriel Carles2, Léo Pomar5. 1. Department of Obstetrics and Gynaecology, West French Guiana Hospital Center, Saint-Laurent-du-Maroni, French Guiana. Electronic address: hcininajeh@gmail.com. 2. Department of Obstetrics and Gynaecology, West French Guiana Hospital Center, Saint-Laurent-du-Maroni, French Guiana. 3. Assistance Publique-Hôpitaux de Paris, Service de Gynécologie-Obstétrique, Hôpital Louis Mourier, Colombes, France. Université de Paris. Inserm IAME-U1137, Paris, France. Groupe de Recherche sur les Infections pendant la grossesse (GRIG). 4. Department of Biology, West French Guiana Hospital Center, Saint-Laurent-du-Maroni, French Guiana. 5. Materno-Fetal and Obstetrics Research Unit, Department "Woman-Mother-Child", Lausanne University Hospital, Lausanne, Switzerland.
Abstract
OBJECTIVE: To describe the proportions of asymptomatic, mild and severe diseases in infected pregnant women admitted for delivery. To compare maternal, fetal and neonatal outcomes of SARS-CoV-2 infected pregnant women with those of non-infected patients. STUDY DESIGN: Through an universal PCR testing for SARS-COV-2 at admission (not symptoms-based), this prospective cohort study enrolled all pregnant women admitted for delivery between 16th of June and the 16th of August 2020 in the West French Guiana Hospital Center. RESULTS: 507 pregnant women were included during the study period, of which 137 (27 %) were infected with SARS-COV-2. On admission, only 34/137 (24.8 %) of these patients presented with clinical symptoms. Among asymptomatic women, 16 /103 (15 %) became symptomatic after diagnosis. Throughout the delivery hospitalization and follow-up, 87/137 (63.5 %) remained always asymptomatic, 45/137 (32.8 %) developed a mild COVID-19 and 5/137 (3.6 %) developed a severe infection. SARS-CoV-2 infected patients were more likely to have post-partum hemorrhage >500 mL (14.2 % vs 7.2 %, RR 2.0 [95 %CI 1.1-3.4]), to be transfused (5.5 % vs 1.1 %, RR 4.9 [1.5-16.6]), and to be hospitalized in ICU (3.6 % vs 0.8 %, RR 4.5 [95 %CI 1.1-18.6] than uninfected ones. Intra-uterine fetal demises were more common in infected mothers compared to controls (5.1 % vs 1.1 %, RR 4.7 [95 % CI 1.4-45.9). Among 108 neonates from infected mothers tested at birth, none tested positive (0/108). When tested between 25 and 42 h after delivery, 4/29 (13.7 %) were positive for SARS-CoV-2 RT-PCR on nasopharyngeal swabs and remained asymptomatic. CONCLUSION: Pregnant women admitted for delivery and diagnosed with a SARS-COV-2 infection through an universal screening were symptomatic in only a quarter of cases. Their risks of post-partum hemorrhage, transfusion and admission to ICU were higher than those of uninfected patients. They also presented a higher risk of intra-uterine fetal demise. There were no other differences in maternal, obstetrical or neonatal outcomes.
OBJECTIVE: To describe the proportions of asymptomatic, mild and severe diseases in infected pregnant women admitted for delivery. To compare maternal, fetal and neonatal outcomes of SARS-CoV-2 infected pregnant women with those of non-infectedpatients. STUDY DESIGN: Through an universal PCR testing for SARS-COV-2 at admission (not symptoms-based), this prospective cohort study enrolled all pregnant women admitted for delivery between 16th of June and the 16th of August 2020 in the West French Guiana Hospital Center. RESULTS: 507 pregnant women were included during the study period, of which 137 (27 %) were infected with SARS-COV-2. On admission, only 34/137 (24.8 %) of these patients presented with clinical symptoms. Among asymptomatic women, 16 /103 (15 %) became symptomatic after diagnosis. Throughout the delivery hospitalization and follow-up, 87/137 (63.5 %) remained always asymptomatic, 45/137 (32.8 %) developed a mild COVID-19 and 5/137 (3.6 %) developed a severe infection. SARS-CoV-2 infectedpatients were more likely to have post-partum hemorrhage >500 mL (14.2 % vs 7.2 %, RR 2.0 [95 %CI 1.1-3.4]), to be transfused (5.5 % vs 1.1 %, RR 4.9 [1.5-16.6]), and to be hospitalized in ICU (3.6 % vs 0.8 %, RR 4.5 [95 %CI 1.1-18.6] than uninfected ones. Intra-uterine fetal demises were more common in infected mothers compared to controls (5.1 % vs 1.1 %, RR 4.7 [95 % CI 1.4-45.9). Among 108 neonates from infected mothers tested at birth, none tested positive (0/108). When tested between 25 and 42 h after delivery, 4/29 (13.7 %) were positive for SARS-CoV-2 RT-PCR on nasopharyngeal swabs and remained asymptomatic. CONCLUSION: Pregnant women admitted for delivery and diagnosed with a SARS-COV-2 infection through an universal screening were symptomatic in only a quarter of cases. Their risks of post-partum hemorrhage, transfusion and admission to ICU were higher than those of uninfected patients. They also presented a higher risk of intra-uterine fetal demise. There were no other differences in maternal, obstetrical or neonatal outcomes.
Authors: Jean B Nachega; Nadia A Sam-Agudu; Rhoderick N Machekano; Philip J Rosenthal; Sonja Schell; Liesl de Waard; Adrie Bekker; Onesmus W Gachuno; John Kinuthia; Nancy Mwongeli; Samantha Budhram; Valerie Vannevel; Priya Somapillay; Hans W Prozesky; Jantjie Taljaard; Arifa Parker; Elizabeth Agyare; Akwasi Baafuor Opoku; Aminatu Umar Makarfi; Asara M Abdullahi; Chibueze Adirieje; Daniel Katuashi Ishoso; Michel Tshiasuma Pipo; Marc B Tshilanda; Christian Bongo-Pasi Nswe; John Ditekemena; Lovemore Nyasha Sigwadhi; Peter S Nyasulu; Michel P Hermans; Musa Sekikubo; Philippa Musoke; Christopher Nsereko; Evans K Agbeno; Michael Yaw Yeboah; Lawal W Umar; Mukanire Ntakwinja; Denis M Mukwege; Etienne Kajibwami Birindwa; Serge Zigabe Mushamuka; Emily R Smith; Edward J Mills; John Otokoye Otshudiema; Placide Mbala-Kingebeni; Jean-Jacques Muyembe Tamfum; Alimuddin Zumla; Aster Tsegaye; Alfred Mteta; Nelson K Sewankambo; Fatima Suleman; Prisca Adejumo; Jean R Anderson; Emilia V Noormahomed; Richard J Deckelbaum; Jeffrey S A Stringer; Abdon Mukalay; Taha E Taha; Mary Glenn Fowler; Judith N Wasserheit; Refiloe Masekela; John W Mellors; Mark J Siedner; Landon Myer; Andre-Pascal Kengne; Marcel Yotebieng; Lynne M Mofenson; Eduard Langenegger Journal: Clin Infect Dis Date: 2022-06-08 Impact factor: 20.999
Authors: Geraldo Duarte; Conrado Milani Coutinho; Daniel Lorber Rolnik; Silvana Maria Quintana; Ana Cláudia Rabelo E Silva; Liona C Poon; Fabrício da Silva Costa Journal: AJOG Glob Rep Date: 2021-09-03
Authors: Pavel Babal; Lucia Krivosikova; Lucia Sarvaicova; Ivan Deckov; Tomas Szemes; Tatiana Sedlackova; Michal Palkovic; Anna Kalinakova; Pavol Janega Journal: Viruses Date: 2021-12-19 Impact factor: 5.048